EUROPEAN NEUROLOGICAL REVIEW – VOLUME 12 ISSUE 1 – SUMMER 2017

Welcome to the latest edition of European Neurological Review, which features a diverse range of topical articles covering a variety of therapeutic areas. This edition begins with a timely editorial from Milonas on recent advances in multiple sclerosis (MS), which is also the subject of two other articles. Kesselring discusses the concept of neurorehabilitation in […]

Multiple sclerosis (MS) is a chronic autoimmune demyelinating disorder of the central nervous system (CNS), mainly affecting young people. An increasing number of disease modifying treatments (DMTs) is currently available, aiming to control the disease activity, i.e., the inflammatory demyelinating attacks in the CNS parenchyma clinically expressed as relapses and the ongoing disability progression. Thanks […]

Levodopa therapy and other dopamine replacement therapies (DRTs) have remained the cornerstone for the treatment of Parkinson’s disease (PD) since the 1960s.1 Many motor symptoms of PD can be partially reversed by DRT as well as more invasive therapies such as deep brain stimulation (DBS) of the subthalamic nucleus. However, many challenges remain both in […]

As the armamentarium of anti-epileptic drugs (AEDs) continues to expand, epilepsy management is becoming increasingly complex. This necessitates multiple considerations for the choice of the most appropriate AED that can broadly be organised into five categories: (i) rational treatment selection (taking into account mode of action of AEDs); (ii) efficacy with respect to seizure control […]

Several studies have demonstrated the relationship between odours and primary headaches.1–31 Generally, we observed a severe intolerance to odours, pleasant or unpleasant, during headache attacks.2,4–8,10,11,13–30 However, a limited number of studies showed that odours may trigger headache attacks in some patients, particularly in migraineurs 1,3,6,7,9,24 and occasionally in cluster headache patients.12,18 This intolerance to odours […]

It has been recognised for centuries that symptoms outside of pain are reported with migraine.1 Symptoms prior to the onset of migraine headache have been called premonitory or prodromal symptoms and the symptoms after headache resolution have been called postdromal or resolution symptoms in the literature.2–4 These symptoms are likely to be a continuum, starting […]

Approaches to managing multiple sclerosis (MS) are changing rapidly and are achieving markedly improved efficacy in inhibiting the disease process.1–3 As a result, treatment goals have progressed beyond halting disability progression. The most apparent reason for these achievements is the increasing use of disease-modifying drugs (DMDs) and the emergence of new DMDs that are more […]

Multiple sclerosis (MS) is a chronic, progressive disease of the central nervous system (CNS), resulting from inflammatory lesions that become sites of demyelination and axonal injury. These lesions are associated with infiltrating T cells and monocytes, as well as B cells and plasma cells.1 Treatment of MS presents a challenge, since disease-modifying treatments (DMTs) must […]